Biopharmaceutical Company Announces Preclinical Data For Chronic Neuropathic Epilepsy

Trevena, Inc., a biopharmaceutical company listed on the Nasdaq under the ticker symbol TRVN, has announced compelling preclinical data from two collaborative research efforts aimed at understanding the efficacy of their novel therapeutic candidate, TRV045. These studies focus on chronic neuropathic pain and epilepsy, two complex central nervous system (CNS) disorders that significantly affect patients' quality of life. $Trevena(TRVN.US)$